Oral azacitidine significantly improved RBC-TI rates and induced durable bilineage improvements in patients with lower-risk MDS and high-risk disease features, according to a phase 3 trial.
True or false: Experts recommend the use of serum procalcitonin as a disease biomarker in patients with MPNs.
When initiated early in the course of the disease, decitabine with or without ruxolitinib has shown clinical benefit in patients with advanced phases of MPNs.
Study findings lead experts to recommend against the use of serum procalcitonin (PCT) as a disease biomarker in patients with MPNs.
During the virtual Great Debates & Updates in Hematologic Malignancies, Dr Pemmaraju discussed new therapies for myeloproliferative neoplasms (MPNs) with a focus on CMML.
True or False: The addition of azacitidine to eprenetapopt led to significantly low rates of response and remission in a study of patients with TP53-mutant MDS and oligoblastic AML.
Is there a significant link between serum ferritin level and fibrosis in older patients with MF?
Study findings showed that vedolizumab 300 mg was tolerable and led to low incidence of overall and lower-intestinal aGVHD in patients who undergo allo-HSCT.
Study findings suggest that eprenetapopt plus azacitidine is well-tolerated and leads to high rates of response and remission in patients with TP53-mutant MDS and oligoblastic AML.